These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Early stopping of clinical trials. Cuzick J; Howell A; Forbes J Breast Cancer Res; 2005; 7(5):181-3. PubMed ID: 16168134 [TBL] [Abstract][Full Text] [Related]
24. Early viewing of noninferiority trials in progress. Dignam JJ J Clin Oncol; 2005 Aug; 23(24):5461-3. PubMed ID: 16027438 [No Abstract] [Full Text] [Related]
25. Independence of the statistician who analyses unblinded data. Siegel JP; O'Neill RT; Temple R; Campbell G; Foulkes MA Stat Med; 2004 May; 23(10):1527-9. PubMed ID: 15122732 [TBL] [Abstract][Full Text] [Related]
26. [Public clinical trials: which kind of monitoring should be used?]. Cornu C; Binquet C; Thalamas C; Vigouroux C; Gaillard S; Ginhoux T; Vaz B; Jossan C; Félin A; Sailly A; Gueyffier F; Journot V; Kassaï B Therapie; 2013; 68(3):135-41. PubMed ID: 23886457 [TBL] [Abstract][Full Text] [Related]
27. The independent statistician for data monitoring committees. DeMets DL; Fleming TR Stat Med; 2004 May; 23(10):1513-7. PubMed ID: 15122729 [TBL] [Abstract][Full Text] [Related]
28. The statistician and the data monitoring committee. D'Agostino RB Stat Med; 2004 May; 23(10):1501-2. PubMed ID: 15122726 [No Abstract] [Full Text] [Related]
29. Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership? Ellenberg SS; George SL Stat Med; 2004 May; 23(10):1503-5. PubMed ID: 15122727 [TBL] [Abstract][Full Text] [Related]
30. Stopping clinical trials early for benefit: impact on estimation. Freidlin B; Korn EL Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463 [TBL] [Abstract][Full Text] [Related]
31. Considerations in developing data and safety monitoring plans: a framework. Zucker DR J Investig Med; 2004 Nov; 52(7):443-5. PubMed ID: 15651259 [No Abstract] [Full Text] [Related]
32. Continuous toxicity monitoring in phase II trials in oncology. Ivanova A; Qaqish BF; Schell MJ Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702 [TBL] [Abstract][Full Text] [Related]
33. Issues in the use of adaptive clinical trial designs. Emerson SS Stat Med; 2006 Oct; 25(19):3270-96; discussion 3302-4, 3320-5, 3326-47. PubMed ID: 16906553 [TBL] [Abstract][Full Text] [Related]
34. [Treatment of acute myeloid leukemia--focusing on the data from JALSG studies]. Miyawaki S Rinsho Ketsueki; 2008 Oct; 49(10):1386-93. PubMed ID: 18833923 [No Abstract] [Full Text] [Related]
35. Playing safe and preserving integrity: making the FDA model work. Wittes J Stat Med; 2004 May; 23(10):1523-5. PubMed ID: 15122731 [TBL] [Abstract][Full Text] [Related]
36. When should an interim analysis be unblinded to the data monitoring committee? Knottnerus JA; Spigt MG J Clin Epidemiol; 2010 Apr; 63(4):350-2. PubMed ID: 19762210 [No Abstract] [Full Text] [Related]
37. Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board. Wittes J; Barrett-Connor E; Braunwald E; Chesney M; Cohen HJ; Demets D; Dunn L; Dwyer J; Heaney RP; Vogel V; Walters L; Yusuf S Clin Trials; 2007; 4(3):218-34. PubMed ID: 17715247 [TBL] [Abstract][Full Text] [Related]
38. A 25-year review of sequential methodology in clinical studies. Todd S Stat Med; 2007 Jan; 26(2):237-52. PubMed ID: 17139691 [TBL] [Abstract][Full Text] [Related]
39. Challenging Issues in Clinical Trial Design: Part 4 of a 4-Part Series on Statistics for Clinical Trials. Pocock SJ; Clayton TC; Stone GW J Am Coll Cardiol; 2015 Dec; 66(25):2886-2898. PubMed ID: 26718676 [TBL] [Abstract][Full Text] [Related]
40. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome. Zhao Y; Grambsch PM; Neaton JD Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]